ERBB2 and breast carcinoma: This study aimed to determine the temporal changes in mitochondrial function, oxidative stress, and cell death in isolated PBMCs throughout the clinical course of HER2-positive breast cancer patients receiving sequential doxorubicin and trastuzumab treatment.